Cencora (COR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $4.48
- Estimate
- $4.35
- Surprise
- +3.0%
- Revenue (period 2026-06-30)
- $84.75B
- Score today
- 4.9/10
Revenue source: xbrl.
How the report landed
Cencora (COR) beat the $4.35 estimate with adjusted EPS of $4.48 — a clear 3.0% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates COR Sell at 4.9/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +3.0% surprise compares with a +1.5% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Customer: top ten customers (66.0%)
- Target reached (-1.0% upside)
- Quality below floor (3.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $324.35
- Stop
- $311.59
The stock trades at 24.1× trailing but 16.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
COR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Distribution
- Market cap
- $61.89B
- P/E (fwd)
- 16.4
- P/E (ttm)
- 24.1
- 52-week range
- $244.82–$377.54
- Off 52-week high
- 14.1%
- RSI (14)
- 53
- Volume vs avg
- 0.91×
- Score today
- 4.9/10